What is HC Wainwright’s Forecast for Evotec Q1 Earnings?

Evotec AG (NASDAQ:EVO) – HC Wainwright issued their Q1 2027 EPS estimates for shares of Evotec in a report issued on Friday, August 14th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings of ($0.01) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Evotec’s current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Evotec’s Q2 2027 earnings at $0.00 EPS, Q3 2027 earnings at $0.02 EPS, Q4 2027 earnings at $0.03 EPS, FY2027 earnings at $0.04 EPS and FY2028 earnings at $0.32 EPS.

Several other analysts have also recently weighed in on EVO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evotec in a research report on Tuesday, July 21st. TD Cowen cut Evotec from a “buy” rating to a “hold” rating and set a $2.00 target price for the company. in a research note on Wednesday, July 15th. Berenberg Bank lowered Evotec from a “buy” rating to a “hold” rating in a research report on Thursday, July 16th. Finally, Wall Street Zen lowered Evotec from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $3.00.

Evotec Price Performance

Shares of EVO opened at $1.91 on Monday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.21 and a current ratio of 2.33. Evotec has a one year low of $1.89 and a one year high of $4.27. The company has a 50-day simple moving average of $2.34 and a two-hundred day simple moving average of $2.77.

Institutional Investors Weigh In On Evotec

Hedge funds have recently bought and sold shares of the business. Apollon Wealth Management LLC bought a new position in shares of Evotec during the first quarter valued at approximately $28,000. BNP Paribas Financial Markets lifted its holdings in shares of Evotec by 62.2% during the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after purchasing an additional 4,600 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after purchasing an additional 9,289 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Evotec in the 4th quarter worth approximately $40,000. Finally, XTX Topco Ltd bought a new stake in shares of Evotec in the 2nd quarter worth approximately $66,000. Institutional investors own 5.81% of the company’s stock.

Trending Headlines about Evotec

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $4.00 price target for Evotec, implying substantial upside from recent trading levels. The firm still expects a return to profitability in the longer term, forecasting positive EPS in fiscal 2029 and 2030. HC Wainwright Weighs in on Evotec’s Q1 Earnings
• Neutral Sentiment: HC Wainwright’s current full-year consensus reference remains a loss of $0.98 per share, while its estimates call for a $0.83-per-share loss in fiscal 2026. The forecasts indicate analysts continue to expect near-term losses before a potential recovery.
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across multiple periods: Q3 and Q4 2026 estimates were reduced to losses of $0.14 per share, from losses of $0.04 and $0.02, respectively. Its fiscal 2026 estimate was cut to a $0.83 loss from $0.31, while fiscal 2029 and 2030 estimates were reduced to $0.21 and $0.28 from $0.33 and $0.48. The broad downward revisions suggest weaker expected earnings and may weigh on investor sentiment.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.